SHR-1701 in Combination With Chemotherapy and Radiotherapy in Locally Advanced Rectal Cancer
Status:
Not yet recruiting
Trial end date:
2026-10-31
Target enrollment:
Participant gender:
Summary
This study will evaluate the efficacy and safety of SHR-1701 combined with radiotherapy and
chemotherapy as perioperative treatment for locally advanced rectal cancer. Eligible patients
will receive standard chemoradiation with SHR-1701 followed by XELOX combined with SHR-1701.
In all subjects, restaging pelvic MRI with chest and abdominal CT will be performed after
completion of neoadjuvant treatment to determine resectability and to rule out any evidence
of metastases. Subjects who have resectable disease will undergo surgery. Adjuvant XELOX
combined with SHR-1701 will be given after surgery.